NCT01630018 - Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG

Topotecan

1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression

DRUG

Belotecan

0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression

Trial Locations (1)

Seoul National University Hospital, Seoul